Makers of medical device implants and diagnostic products proved health care was no monolith after broadly outperforming the U.S. market and their health care brethren in 2018. But 2019 is shaping up quite differently through the first day of trading amid a spotlight from a variety of investment banks.
Takeda Pharmaceutical Co. is considering a sale of some emerging-market drugs, as the Japanese drugmaker expands a push to cut debt after its $62 billion takeover of Shire Plc, people familiar with the matter said.
Insulin-producing cells more responsive to fluctuating glucose levels
A French court canceled the license for one of Monsanto’s glyphosate-based weedkillers on Tuesday over safety concerns, placing an immediate ban on Roundup Pro 360 in the latest legal blow to the Bayer-owned business.